Superworth

Amneal Pharmaceuticals AMRX

Drug Manufacturers - General, Healthcare
$20.44
−4.97%
Market cap
$6.5B
PE
41.7×
6y median 51.4×
Forward PE
n/m
not a meaningful number
Price to sales
2.1×
EV/EBIT
18.4×
Revenue, 12 months
$3.1B
+9% on a year ago
Net margin
5.0%
Free cash flow yield
2.0%

Amneal Pharmaceuticals trades at 41.7× trailing earnings, cheaper than 67% of the last ten years. Revenue was $3.1B over the last twelve months, up 9% on a year earlier with a 5% net margin.

Charts

Financials

Income statement for AMRX, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$620M+14%$617M+1%$659.2M+18%$701.8M+17%$702.5M+13%$730.5M+18%$695.4M+6%$724.5M+3%$784.5M+12%$814.3M+12%$722.5M+4%$796.2M+10%
Cost of revenue$387.5M+10%$427.2M+8%$421.1M+11%$451.8M+19%$432.9M+12%$467.6M+10%$439.5M+4%$438.3M−3%$510.5M+18%$517.1M+11%$402.4M−8%$461.7M+5%
Gross profit$232.5M+20%$189.8M−12%$238.1M+34%$249.9M+14%$269.6M+16%$262.9M+39%$255.9M+8%$286.3M+15%$274M+2%$297.2M+13%$320.1M+25%$334.5M+17%
R&D$41.4M−18%$46.1M+10%$39.3M+2%$36.1M−5%$61.1M+48%$54.3M+18%$40M+2%$48M+33%$63.4M+4%$34.8M−36%$38.4M−4%$39M−19%
SG&A$113M+13%$109M+7%$112.6M+10%$116.5M+10%$118.7M+5%$128.7M+18%$118.3M+5%$124.3M+7%$137.8M+16%$146.5M+14%$138.9M+17%$148.7M+20%
$75.6M+71%$14.2M−61%−$10.7M$95.5M+19%$88.8M+17%$75.8M+434%$100.3M$111.4M+17%$70.3M−21%$112M+48%$141.8M+41%$129.8M+17%
Interest expense$50.9M+20%$59.5M+27%$65.7M+33%$65.7M+29%$65.5M+29%$61.7M+4%$56.9M−13%$65.1M−1%$62.8M−4%$56.2M−9%$53.4M−6%$55M−15%
Pre-tax income$23M+953%−$83.5M+990%−$75.5M+701%$20.4M−31%$15.4M−33%−$15.3M−82%$37.5M$51.7M+153%−$5.2M$55.2M$80.2M+114%$71M+37%
−$2.1M$9.9M$6.2M+822%$3.6M$3.7M$5.4M−45%$12.9M+109%$16.1M+345%−$23.4M$5.7M+4%$2.2M−83%$1.4M−92%
Net income$9.7M−$98.6M+2177%−$91.6M+1220%$6M−50%−$156K−$31.1M−69%$12.2M$22.4M+274%$2.4M$35.1M$62.3M+411%$57.7M+157%
$0.06−$0.40+1233%−$0.30+500%$0.02−75%$0.00−$0.10−75%$0.04$0.07+250%$0.01$0.11$0.19+375%$0.18+157%
159.7M+6%243.7M+61%307.3M+102%319M+106%309.6M+94%309.9M+27%324M+5%322.4M+1%324.8M+5%328.1M+6%328.9M+2%328.1M+2%

Revenue: Q1 FY17: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY17: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY17: 6 months less the 3 months printed beside them.

R&D: Q1 FY17: 6 months less the 3 months printed beside them.

SG&A: Q1 FY17: 6 months less the 3 months printed beside them.

Operating income: Q1 FY17: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY17: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY17: 6 months less the 3 months printed beside them.

Income tax: Q1 FY17: 6 months less the 3 months printed beside them.

Net income: Q1 FY17: 6 months less the 3 months printed beside them.

EPS, diluted: 8 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 7 periods, Q4 FY18 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×2.1×+9%5.0%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
KNSAKiniksa Pharmaceuticals International$7.1B93.6×87.6×8.4×+59%9.6%
ALKSAlkermes plc.$7.5B118×16.0×4.5×+11%4.0%
CORTCorcept Therapeutics$8.7B192×28.3×10.5×+16%6.6%
PTGXProtagonist Therapeutics$9B135×60.1×32.0×+35%29.4%
TGTXTG Therapeutics$9.2B21.9×19.6×11.5×+76%55.2%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
BMRNBiomarin Pharmaceutical$11.1B155×72.5×3.3×+11%2.1%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
Peer median$7.3B106×43.5×8.4×+35%19.5%

More on Amneal Pharmaceuticals

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .